Copyright
©The Author(s) 2016.
World J Hepatol. Oct 8, 2016; 8(28): 1200-1204
Published online Oct 8, 2016. doi: 10.4254/wjh.v8.i28.1200
Published online Oct 8, 2016. doi: 10.4254/wjh.v8.i28.1200
Right hepatectomy | Left hepatectomy | |||||||
n | Regeneration rate (%)1 | P | n | Regeneration rate (%)1 | P | |||
Age (mean) | 45-83 (69) | P = 0.891 | 46-89 (69) | P = 0.321 | ||||
Sex (male/female) | 18/8 | 65.6/69.2 | P = 0.355 | 20/12 | 25.7/25.9 | P = 0.969 | ||
Background liver disease (yes/no) | 6/20 | 51.0/70.2 | P = 0.248 | 14/18 | 24.0/25.7 | P = 0.621 | ||
Platelet count (/mm3) ≥ 100 | 24 | 69.3 | P = 0.178 | 30 | 24.7 | P = 0.586 | ||
< 100 | 2 | 41.6 | 2 | 28.8 | ||||
Total bilirubin (mg/dL ) ≥ 1.5 | 1 | 71.8 | P = 0.842 | 4 | 28.2 | P = 0.724 | ||
< 1.5 | 25 | 64.4 | 27 | 24.9 | ||||
ICG-R15 (%) ≥ 20 | 4 | 28.5 | P < 0.05 | 4 | 28.2 | P = 0.724 | ||
< 20 | 22 | 72.7 | 27 | 24.9 | ||||
Diabetes mellitus (yes/no) | 4/22 | 63.7/65.6 | P = 0.570 | 4/28 | 37.8/24.7 | P = 0.459 | ||
Preoperative chemotherapy (yes/no) | 10/16 | 60.0/74.5 | P = 0.317 | 8/24 | 29.7/24.1 | P = 0.361 |
n | Hypertrophic rate (%)1 | P | ||
Age (mean) | 50–80 (65) | P = 0.845 | ||
Sex (male/female) | 10/3 | 30.5/40.1 | P = 0.612 | |
Background liver disease (yes/no) | 6/7 | 23.1/40.1 | P = 0.087 | |
Platelet count (/mm3) ≥ 100 | 12 | 30.5 | P = 0.593 | |
< 100 | 1 | 40.1 | ||
Total bilirubin (mg/dL) ≥ 1.5 | 4 | 19.7 | P < 0.05 | |
< 1.5 | 9 | 40.0 | ||
ICG-R15 (%) ≥ 20 | 2 | 12.0 | P < 0.05 | |
< 20 | 11 | 34.2 | ||
Diabetes mellitus (yes/no) | 3/10 | 32.2/31.4 | P = 1.000 | |
Preoperative chemotherapy (yes/no) | 3/10 | 40.1/26.8 | P = 0.237 |
- Citation: Kageyama Y, Kokudo T, Amikura K, Miyazaki Y, Takahashi A, Sakamoto H. Impaired liver function attenuates liver regeneration and hypertrophy after portal vein embolization. World J Hepatol 2016; 8(28): 1200-1204
- URL: https://www.wjgnet.com/1948-5182/full/v8/i28/1200.htm
- DOI: https://dx.doi.org/10.4254/wjh.v8.i28.1200